Rubedo Life Sciences has announced promising preliminary results from its Phase 1 clinical trial of RLS-1496, a first-in-class GPX4 modulator targeting aging cells in patients with plaque psoriasis, atopic dermatitis, and photo-aged skin. Conducted in the European Union, the trial met its primary endpoint, demonstrating safety and tolerability, while also revealing early efficacy signals, including a reduction in senescent cells and inflammatory cytokines.

These findings are significant for the longevity and healthspan field, as they highlight RLS-1496’s potential to rejuvenate aging skin and address chronic inflammatory conditions. The trial showed a clear dose-response relationship, with the highest dose leading to substantial clinical improvements in both psoriasis and atopic dermatitis patients. Notably, the drug’s ability to engage GPX4 and reduce epidermal thickness suggests a mechanistic link to cellular rejuvenation, a growing area of interest in therapeutic development.

The key takeaway from this trial is the potential of RLS-1496 as a novel therapeutic avenue for treating age-related skin conditions and chronic inflammation, marking a significant step in the application of senotherapeutics in clinical settings. As Rubedo prepares for further studies, including a Phase 1b/2a trial in actinic keratosis, the implications for aging research and therapeutic strategies are substantial.

Source: lifespan.io